Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 2 Utility scores

From: Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses

Status

Utility value

Comments

Remission

0.799 [28]

 

Relapse

0.670 [28]

 

Acute EPS (extra-pyramidal symptoms)

0.7095

Calculated by multiplying remission utility by expected decrement in utilities estimated in the NICE guidance [18] (0.888 for acute EPS and 0.959 for weight gain)

Weight gain

0.7662

 

Diabetes Mellitus (controlled)

0.760 [29]

 

Diabetes Mellitus complications

Disutility value [30]

 

Amputation

-0.109

 

Fatal myocardial infarction

1.000

 

Heart failure

-0,108

 

Ischaemic heart disease

-0.132

 

Non-fatal myocardial infarction

-0.129

 

Non-fatal Stroke

-0.181